文献速递胸部肿瘤

Onartuzumab联合厄洛替尼对比厄洛替尼治疗既往经治的IIIB或IV期非小细胞肺癌的III期随机试验(METLung)结果

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
PubMed 文献 · J Clin Oncol · 2016-12-12

III期METLung研究纳入499例经铂类化疗后进展的MET免疫组化阳性局部晚期或转移性非小细胞肺癌患者,随机接受Onartuzumab联合厄洛替尼或安慰剂联合厄洛替尼。Onartuzumab组中位OS为6.8个月,对照组为9.1个月(分层HR 1.27,95%CI 0.98-1.65,P=.067),未改善临床结局。

要点

  • Onartuzumab联合厄洛替尼组中位OS 6.8个月,对照组9.1个月,分层HR 1.27(95%CI 0.98-1.65),未达统计学显著。
  • 中位PFS分别为2.7个月与2.6个月(分层HR 0.99,95%CI 0.81-1.20,P=.92),ORR分别为8.4%与9.6%。
  • 探索性分析显示MET FISH状态和基因表达亚组未见Onartuzumab获益,EGFR突变患者有OS缩短趋势(HR 4.68,95%CI 0.97-22.63)。

核心结论

  • Onartuzumab联合厄洛替尼未改善MET阳性非小细胞肺癌患者的临床结局,且Onartuzumab组OS较厄洛替尼组缩短。

研究设计与样本

  • III期随机试验OAM4971g(METLung),纳入499例经铂类化疗后进展的MET免疫组化阳性局部晚期或转移性非小细胞肺癌患者。
  • 患者按1:1随机分配至Onartuzumab(15 mg/kg静脉注射,每21天周期第1天)联合每日口服厄洛替尼150 mg组(n=250)或静脉安慰剂联合每日口服厄洛替尼150 mg组(n=249)。
  • 主要终点为意向治疗人群的总生存期(OS);次要终点包括中位无进展生存期、总缓解率、生物标志物分析和安全性。

主要发现

  • Onartuzumab组 vs 安慰剂组中位OS为6.8个月 vs 9.1个月(分层HR 1.27,95%CI 0.98-1.65,P=.067),Onartuzumab组死亡人数更多(130例[52%] vs 114例[46%])。
  • Onartuzumab组 vs 安慰剂组中位PFS为2.7个月 vs 2.6个月(分层HR 0.99,95%CI 0.81-1.20,P=.92)。
  • Onartuzumab组 vs 安慰剂组总缓解率分别为8.4% vs 9.6%。
  • 探索性分析使用MET荧光原位杂交状态和基因表达,显示Onartuzumab无获益;EGFR突变患者接受Onartuzumab治疗有OS缩短趋势(HR 4.68,95%CI 0.97-22.63)。
  • 实验组 vs 对照组3-5级不良事件发生率分别为56.0% vs 51.2%,严重不良事件分别为33.9% vs 30.7%。

关键数值与推荐

  • Onartuzumab组 vs 安慰剂组中位OS 6.8个月 vs 9.1个月(分层HR 1.27,95%CI 0.98-1.65,P=.067)。
  • Onartuzumab组 vs 安慰剂组中位PFS 2.7个月 vs 2.6个月(分层HR 0.99,95%CI 0.81-1.20,P=.92)。
  • Onartuzumab组 vs 安慰剂组总缓解率8.4% vs 9.6%。
  • EGFR突变患者接受Onartuzumab治疗有OS缩短趋势(HR 4.68,95%CI 0.97-22.63)。
  • 实验组 vs 对照组3-5级不良事件发生率56.0% vs 51.2%,严重不良事件33.9% vs 30.7%。

临床怎么用

  • Onartuzumab联合厄洛替尼未改善MET阳性非小细胞肺癌患者的临床结局,原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic non-small-cell lung cancer selected by MET immunohistochemistry whose disease had progressed after treatment with a platinum-based chemotherapy regimen. Patients and Methods Patients were randomly assigned at a one-to-one ratio to receive onartuzumab (15 mg/kg intravenously on day 1 of each 21-day cycle) plus daily oral erlotinib 150 mg or intravenous placebo plus daily oral erlotinib 150 mg. The primary end point was overall survival (OS) in the intent-to-treat population. Secondary end points included median progression-free survival, overall response rate, biomarker analysis, and safety. Results A total of 499 patients were enrolled (onartuzumab, n = 250; placebo, n = 249). Median OS was 6.8 versus 9.1 months for onartuzumab versus placebo (stratified hazard ratio [HR], 1.27; 95% CI, 0.98 to 1.65; P = .067), with a greater number of deaths in the onartuzumab arm (130 [52%] v 114 [46%]). Median progression-free survival was 2.7 versus 2.6 months (stratified HR, 0.99; 95% CI, 0.81 to 1.20; P = .92), and overall response rate was 8.4% and 9.6% for onartuzumab versus placebo, respectively. Exploratory analyses using MET fluorescence in situ hybridization status and gene expression showed no benefit for onartuzumab; patients with EGFR mutations showed a trend toward shorter OS with onartuzumab treatment (HR, 4.68; 95% CI, 0.97 to 22.63). Grade 3 to 5 adverse events were reported by 56.0% and 51.2% of patients, with serious AEs in 33.9% and 30.7%, for experimental versus control arms, respectively. Conclusion Onartuzumab plus erlotinib did not improve clinical outcomes, with shorter OS in the onartuzumab arm, compared with erlotinib in patients with MET-positive non-small-cell lung cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Spigel DR, Edelman MJ, O'Byrne K, et al. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. J Clin Oncol. 2016. PMID: 27937096. doi:10.1200/JCO.2016.69.2160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。